RATES OF ORAL ANTICOAGULANT USE, WHILE IMPROVING OVER TIME, REMAIN LOW AMONG HOSPITALIZED PATIENTS WITH ATRIAL FIBRILLATION

Background: Oral anticoagulant (OAC) under-treatment for stroke prevention in atrial fibrillation (AF) has been demonstrated. Limited data are available on treatment trends treatment over time, as non-vitamin K antagonists (NOACs) were introduced. Methods: Included patients from the Premier Health